No quarterly revenue total was found in LIMINATUS PHARMA, INC.'s SEC filings.
Liminatus Pharma, Inc. (LIMN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $3.0 million in cash and investments and $1.4 million in total debt.
Revenue
—
Net income
$-1.41M
-1342.2% vs year-ago quarter
Operating cash flow
$-969,999
+89.0% vs year-ago quarter
Free cash flow
$-386,847
+37.0% vs prior quarter
EPS
$-0.03
Dividend per share
None
Shares outstanding
67.16M
+148.1% vs year-ago quarter
Net cash
$1.57M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LIMN (Nasdaq), LIMNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971387
- Former names
- Iris Parent Holding Corp. (until Feb 7, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.4M | -$1.1M | -$884,211 | -$701,170 | -$1.1M |
| Net income | -$1.4M | -$1.1M | -$8.2M | -$1.8M | $113,287 |
| Diluted EPS | -$0.03 | -$0.03 | -$0.30 | -$0.07 | $0.00 |
| Operating cash flow | -$969,999 | -$2.0M | -$386,847 | -$600,612 | -$8.8M |
| Free cash flow | — | — | -$386,847 | -$613,720 | — |
| Total assets | $3.4M | $2.8M | $512,795 | $1.3M | $1.9M |
| Total liabilities | $3.1M | $2.9M | $10.3M | $3.0M | $10.7M |
| Stockholders' equity | $300,612 | -$132,596 | -$9.8M | -$1.6M | -$8.8M |
| Cash and investments | $3.0M | $1.9M | $337,655 | $724,502 | $1.3M |
| Total debt | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Listing notice, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Jul 30, 2026 | Jul 29, 2026 |
All 109 Liminatus Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.